Build

FDA Pharmacy Compounding Advisory Committee to review BPC-157, TB-500, MOTS-c, KPV, DSIP, Semax & Epitalon for the 503A Bulks List (July 23–24, 2026)

3 min read

FDA PCAC to review 7 research peptides for the 503A Bulks List (July 23–24, 2026)

Provenance: U.S. regulatory event (FDA advisory-committee meeting) — NOT clinical efficacy evidence

Primary source is the FDA.gov Advisory Committee Calendar page (content current 2026-06-29), which posts the agenda, the public docket (FDA-2025-N-6895), and a downloadable FDA briefing document for each of the 7 peptides. Corroborated by the HHS/RFK Jr. Category-2 announcement (Feb 27 2026), National Law Review, Lengea Law, Pharmacy Times and BSCG. A PCAC recommendation is advisory and non-binding — it is not an approval and not an efficacy/safety finding.

Key findings

  • The FDA’s Pharmacy Compounding Advisory Committee (PCAC) meets July 23–24, 2026 (White Oak, Silver Spring MD + webcast) to advise whether 7 peptides belong on the §503A Bulk Drug Substances List — the step that would give compounding pharmacies a formal, legal prescription pathway.
  • July 23 agenda and the single FDA-reviewed use per substance: BPC-157 (ulcerative colitis), KPV (wound healing & inflammatory conditions), TB-500 (wound healing), MOTs-C (obesity & osteoporosis). Each nominated as free base + acetate.
  • July 24 agenda: Emideltide / DSIP (opioid withdrawal, chronic insomnia, narcolepsy), Semax (cerebral ischemia, migraine, trigeminal neuralgia), Epitalon (insomnia).
  • FDA has posted a briefing document per peptide (BPC-157 3.64 MB, TB-500 1.88 MB, MOTS-c 2.23 MB, KPV, Emideltide, Semax, Epitalon) — the agency’s own evidence review ahead of the vote. Public docket FDA-2025-N-6895 closed to the Committee on July 9, to FDA on July 22, 2026.
  • Broader context: on Feb 27 2026, HHS moved a set of peptides off the FDA’s “Category 2” (significant-safety-risk) compounding list; ~12 peptides were removed from Category 2 as of ~April 15 2026 — BPC-157, LL-37, DiHexa, DSIP (Emideltide), Epitalon, GHK-Cu (injectable), KPV, PEG-MGF, Melanotan II, MOTs-C, Semax, TB-500. Removal from Category 2 lifts the explicit prohibition but does not itself place a substance on the 503A list — that requires this PCAC review + FDA rulemaking.

Why it matters for this base

  • This is the single most consequential regulatory event for INDEXA’s core catalog: BPC-157, TB-500, MOTS-C, Epitalon, KPV, Semax, DSIP are all on the July agenda, and GHK-Cu + Melanotan II are on the Category-2-removal list. The outcome shapes the US legal/compounding landscape these peptides sit in.
  • It resolves a previously-uncorroborated claim: the does-tb-500-have-human-trials article (2026-06-27) deliberately omitted an “FDA compounding advisory committee July 23 2026” snippet it couldn’t verify. The FDA.gov page now confirms it — that article and the trust/compliance pillar can cite it.
  • Note the FDA-reviewed uses are a research-literacy goldmine: FDA is evaluating BPC-157 for ulcerative colitis and TB-500/KPV for wound healing — not the athletic-recovery marketing framing.

Caveats

  • Regulatory, not efficacy. A PCAC vote is a non-binding recommendation; FDA may or may not follow it, and any addition to the 503A list still requires rulemaking. Being reviewed ≠ approved ≠ proven. None of these peptides is FDA-approved; all remain research/educational use only here. Outcome unknown at capture (meeting is ~3 weeks out).

Corroborating sources

  • FDA Advisory Committee Calendar (primary) + 7 FDA briefing PDFs (fda.gov/media/193343–193349); docket FDA-2025-N-6895 (Regulations.gov).
  • HHS/RFK Jr. Category-2 announcement (Feb 27 2026); National Law Review (“Tiny Chains, Big Changes”); Lengea Law 503A review explainer; Pharmacy Times (RFK reclassification); BSCG “What’s Changing With Peptide Regulation in 2026”.

Graph View

Backlinks